Kornimate/medical-research-clean huggingface dataset:
solar lentigines treatment with the triple combination cream

Conditions: Lentigo

Summary: background * lentigines are usually the first sign of photoaging and may produce a significant impact on patients' quality of life. * there is no a treatment of choice for this condition. * solar lentigines and melasma share similar physiopathologic characteristics. * the triple combination (tc) cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) has been effective and safe for the treatment of melasma and other hyperpigmented lesions. hypothesis \* the tc cream will be effective and safe for the treatment of solar lentigines on the back of the hands. patients and methods * 22 patients with solar lentigines were selected and their right hand or left hand were selected at random to be treated with either tc cream or tretinoin 0.05% cream once daily for up 12 weeks. * patients were instructed to apply both creams on the whole back of the hand and not only in the lentigines, and to use a broad-spectrum sunscreen (spf 50+, uva-pf 28) daily in both hands. * clinical assessments of target lesion pigmentation, physician's global assessment of improvement and a subject's self-assessment questionnaire were collected for data analysis at weeks 4, 8, and 12 after starting the treatment and 3 month post-treatment. * statistical methods: the ordinally scaled efficacy measures underwent rank transformation and were analyzed by analysis of variance to test the null hypothesis of no differences among treatments. we performed mann-whitney and wilcoxon tests and the xlstat 2009 software was used.


Eligibility criteria:
inclusion criteria: * subjects of both sexes of 30 - 80 years of age. * phototype ii-v. * postmenopausal women of childbearing age or users of any contraception method with negative pregnancy test (beta subunit chorionic gonadotropin in the blood) at baseline and that maintain the contraceptive treatment during the investigation. * subjects with more than 10 solar lentigines on the back of each hand wich were no treated in the last 6 months exclusion criteria: * patients under 30 or over 80 years of age. * skin types i and vi. * less than 10 solar lentigines on the back of each hand. * patients who have received or are receiving any other treatment for lentigines of the back of hands. * women of childbearing age without contraceptive therapy. * pregnancy or lactation. * history of hypersensitivity to any component of the drugs. * simultaneous use of other topical skin lightening. * patient refusal to participate in the study.

Keywords: lentigo hydroquinone tretinoin fluocinolone acetonide
postoperative comput tomography as a predictor of postoperative complications after pancreatic surgery

Conditions: Pancreatectomy

Summary: pancreatectomy represents the classic approach for resectable lesions of the pancreas, duodenum and periampullary region. due to the technical skills required, the complex anatomy and the extreme fragility of the pancreatic parenchyma, pancreatic resection is still considered to be at risk of postoperative complication mainly due to pancreatic juice leaks. anastomotic leaks are the major cause of morbidity and in-hospital mortality due to the activation of pancreatic enzymes and the following infectious and hemorrhagic complications. severe complications negatively affect postoperative outcomes, long-term survival, quality of life, and costs. operative mortality traditionally has been defined as the rate within 30 days or during the initial hospitalization. but in pancreatic surgery mortality rates within 90 days after pancreatic resection are double those at 30 days. in the present study, the investigators sought to evaluate the usefulness of postoperative ct-scan on the seventh postoperative day before discharging the patients to detect undiagnosed postoperative complication.


Eligibility criteria:
inclusion criteria: will be included in this study, patients: * having an indication of pancreatic surgery * in scheduled surgery * agreeing to participate in the research (ie who signed the informed consent to research participation) * \>18yo exclusion criteria: will not be included in this study, patients: * with emergency surgery * protected by law * under 18 years * presenting an against-indications to the scanner: documented severe allergy to contrast material, kidney failure against-showing the contrast medium injection, pregnancy, lactation and/or mri (pacemaker, metallic intraocular foreign body)
how does mindfulness meditation buffer the negative effects of pain and suffering in the covid-19 world? (healthy sample)

Conditions: Catastrophizing Coronavirus (COVID-19)

Summary: both mindfulness meditation and expectancy effects are known to reduce anxiety, stress and catastrophizing, but it is unknown whether and how expectancy effects contribute to the overall effect of mindfulness meditation on these outcomes, especially during significant global events such as the coronavirus pandemic. this study includes four interrelated aims that will probe these effects and interactions.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * able to read and understand english exclusion criteria: * recurrent pain (two or more days in the last month) * chronic pain (pain most days in the last three months) * incomplete or invalid data (response time \< 32 minutes, failing attention checks) * completing the 20-minute training module in \ 90 minutes

Keywords: coronavirus-related catastrophizing
cognitive behavioral therapy for insomnia vs. exposure, relaxation, and rescripting therapy

Conditions: Insomnia; Nightmare; Trauma

Summary: the objective of this project is to determine if directly addressing disturbed sleep and nightmares will impact client reports of suicidal ideation.


Eligibility criteria:
inclusion criteria: * experiences at least one nightmare per week for the past month * having previously experienced a traumatic event * difficulty falling or staying asleep * suicidal ideation * actively under the care of another health care provider exclusion criteria: * untreated obstructive sleep apnea * acute or apparent psychosis * untreated or unstable bipolar disorder * past history of seizure disorder or neurological disorder * intellectual disability * current substance dependence or in past 6 months
neurocognitive risks in children with solid tumors

Conditions: Solid Tumor in Children

Summary: the survival rate of children with cancer has improved significantly in recent years thanks to the progress of different therapies. the neurocognitive sequelae related to treatments and illness are more or less well known. four factors seem to be associated with neurocognitive sequelae: treatment, the tumor itself, environmental factors like the socio-economic status of parents and biological factors. main purpose of the study is to establish a score to assess the risk of neurocognitive sequelae in these children based on these factors (treatment, tumor, and environmental factors)


Eligibility criteria:
inclusion criteria: * patient aged 6 to 16 years and 11 months during the study period * type of pathology: solid tumor * place of treatment and follow-up: gustave roussy * minimum time from the end of the initial treatment: * for patients who have not received treatment with methotrexate: 6 months * for patients being treated with methotrexate: none * obtaining the non-opposition of parents / legal representatives * affiliation to a social security scheme. exclusion criteria: * patients with other pathologies associated with mental retardation (autism, genetic syndrome ...) * patients lost to follow-up * deceased patients * patients treated for a pathology whose prognosis is involved in the very short term (infiltrating glioma of the brainstem, recurrence of the pathology during treatment) * non-french speaking patients
use of esomeprazole in postoperative bariatric surgery patients users and non-users of nonsteroidal anti-inflammatory drugs (nsaids)

Conditions: Postoperative Bariatric Surgery

Summary: phase iv, open-label, multicenter, non-randomized, with 2 non-comparative investigational arms study, carried out in morbid obesity patients who had undergone gastric bypass surgery for body weight reduction


Eligibility criteria:
inclusion criteria: * written informed consent signed and dated * bmi ≥40 kg/m2 or bmi between 35 and 40 kg/m2, but with a severe disease together with obesity * indication for gastric bypass surgery * upper digestive endoscopy prior to surgery not showing esophagitis, erosions, ulcers or neoplasia, examination performed up to 30 days before surgery being considered valid * helicobacter pylori non-infected patients, diagnosed by tests carried out up to 30 days before surgery exclusion criteria: * contraindication for gastric bypass surgery * contraindication to use omeprazole and derivatives * patients carriers of gastrinoma or having hypergastrinemia * patients contraindicated to perform ude * patients with previous esophagogastroduodenal surgery

Keywords: bariatric surgery ulcer prevention
evaluation of intraarticular tranexamic acid to reduction of total blood loss following knee-arthroplasty

Conditions: Blood Loss; Postoperative Blood Loss; Thromboembolic Complications

Summary: a randomized, prospective, placebo-controlled study which aims to evaluate the effect of combined intraarticular and intravenous tranexamic acid on total blood loss following unilateral knee replacement versus only intravenous tranexamic acid.

intravenous (iv) tranexamic acid is already well-established and well-documented regarding significant effect on reducing blood loss following knee replacement. a few studies more shown a similar effect of intraarticular (ia) injected tranexamic acid into the knee joint at the end of surgery for knee replacement. in this study investigators therefore investigate the possible combined effect of added intraarticular tranexamic acid to conventional intravenous tranexamic acid.

Eligibility criteria:
inclusion criteria: * \> 18 years old * unilateral knee replacement * must be able to give oral and written consent exclusion criteria: * general anesthetized * allergic to tranexamic acid * in treatment with the following anticoagulants: adenosine diphosphate receptor inhibitors or vitamin k antagonist within in the last 5 days. factor xa inhibitor and thrombin inhibitor. * use of oral anticonceptive. * reduced kidney function (s-creatinine \> 120 micromol/l) * medicine or alcohol abuse * females with menstruation within the last 12 mounts. * any kind of cancer disease * rheumatoid arthritis * have participated in a clinical trial within the last 30 days.

Keywords: tranexamic acid knee arthroplasty blood loss blood transfusion thrombolic complication total blood loss 24 h after ended surgery. total blood loss 2 days after ended surgery.
engaging the community to reduce preterm birth via adherence to an individualized prematurity prevention plan

Conditions: Preterm Birth

Summary: the purpose of this study is to determine if incorporate ip3 is feasible prior to a larger trial focused on determining efficacy. feasibility will be measured using the re-aim framework4: reach or participation (primary outcome): (a) percent of eligible participants who are successfully recruited and attend at least one group session; effectiveness: retention rate in the intervention; implementation: fidelity to the intervention protocol; maintenance: intervention sustainability based on continued engagement from the participants.

non-hispanic black (nhb) women are 49% more likely to experience a preterm birth (ptb), delivery before 37 weeks. ptb is associated with increased risk of poor short and long-term neonatal outcomes. ptb can occur in multiple clinical scenarios including spontaneous ptb (e.g. preterm labor, preterm pre-labor rupture of membranes) and medically induced preterm labor (e.g. preeclampsia). women with a history of ptb are at 1.5 - 2 fold increased risk for future ptb. there are medical therapies than can reduce the risk of recurrent ptb specific to the presumed etiology of the prior ptb. thus, women with a history of a prior ptb who receive care with duke maternal fetal medicine (mfm) receive and individualized prematurity prevention plan (ip3) to reduce their risk of recurrent ptb. the ip3 plans are often labor intensive with requirements ranging from daily medications, weekly clinic visits, painful injections or invasive ultrasounds. given the increased rate so of ptb among nhb women and some suggestion of decreased adherence in this population1, we previously conducted qualitative studies with nhb women to uncover patient perceived barriers to ip3 adherence2,3. these studies revealed that nhb women with prior preterm birth felt that stress and lack of support were key barriers to preterm birth prevention adherence. stress and limited support made women feel isolated from their peers and community. based on these data we worked with a stakeholder group to develop a patient-centered, community-involved intervention that will increased adherence to an individualized prematurity prevention plan using community-level social supports. the resulting invention titled, engaging the community to reduce preterm birth via adherence to an individualized prematurity prevention plan (incorporate ip3) includes community doula led group social support.

Eligibility criteria:
inclusion criteria: * self describe race as non-hispanic black * history of prior singleton preterm delivery (before 37 weeks gestation * current singleton gestation, with individualized prematurity prevention (ip3) plan. exclusion criteria: * women with anomalous fetuses * age below 18 years * non-english speaking
the laboratory antiplatelet efficacy and clinical outcome registry

Conditions: Platelet Aggregation Onhibitors

Summary: the ongoing lapcor (laboratory antiplatelet efficacy and clinical outcome registry) registry was initiated in 2008 at a tertiary care cardiac center, and consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (pci) was performed on urgent or elective basis.patients were included in the registry after having signed an informed consent for participation. no exclusion criterion has been applied for the registry participation. efficacy of p2y12 receptor antagonists has been measured by quantitative flow cytometric analysis of vasodilator-stimulated phosphoprotein (vasp) phosphorylation according to the manufacturer protocol (platelet vasp; diagnostica stago, biocytex, asnières, france) on a facscan flow cytometer (becton dickinson). occurrence of major adverse cardiac events at 30 days, 6-months and one year follow up has been investigated.


Eligibility criteria:
inclusion criteria: * patients after stent pci treated with p2y12 antagonist * written informed consent exclusion criteria: - none

Keywords: antiplatelets, percutanous coronary intervention, acute coronary syndromes, laboratory efficacy
the impact of anti-tnf exposure on vedolizumab effectiveness

Conditions: Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis

Summary: vedolizumab is a new medication being used for the treatment of crohn's disease and ulcerative colitis. it works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in the gastrointestinal tract. previous studies have shown that patients who have previous exposure to another type of medication for crohn's disease and ulcerative colitis (anti-tnf medications) do not respond to vedolizumab as well as those who have never been exposed. this study will investigate biologic markers in the blood and tissue the help identify possible reasons for this difference.

patients will be enrolled in the study when they are selected to initiate vedolizumab therapy. vedolizumab is an intravenous infusion given at increasing intervals. the first infusion of vedolizumab will be considered baseline. patients may be enrolled at baseline or at colonoscopy prior to the first scheduled infusion of vedolizumab (pre-treatment visit). the standard induction protocol for vedolizumab consists of infusions at week 0 (baseline), week 2, and week 6. vedolizumab, as per standard-of-care, is then continued at an interval of every 8 weeks following induction therapy. vedolizumab treatment will be prescribed as per standard practice and will be prescribed regardless of participation in this study. patients will not receive medication for the sole purpose of this research. treatment decisions including timing of wash out period between anti-tnf and vedolizumab will be made by the subject's physician and not per the research protocol. there will not be a protocolized washout period for patients previously receiving anti-tnf therapy because treatment will be standard of care and per the directing physician. standard of care laboratory tests will be performed by the clinical laboratory at mount sinai hospital. all other measurements will be completed at prometheus therapeutics \& diagnostics in san diego, california or at a takeda identified lab for vedolizumab concentrations and antibodies.

Eligibility criteria:
inclusion criteria: * male and female adults with a diagnosis of inflammatory bowel disease * patients who will be started on vedolizumab therapy as clinically indicated and in discussion with their treating physician will be eligible. patients will not be started on vedolizumab for the sole purpose of this study exclusion criteria: -patients with prior exposure to vedolizumab or natalizumab

Keywords: inflammatory bowel diseases vedolizumab ulcerative colitis crohn's disease madcam1 integrin alpha4beta7
the role of itgam in systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: study to examine the role of itgam molecule in normal control subjects with known genetic variation in the itgam gene.


Eligibility criteria:
inclusion criteria: * males and females, age 18 or older, enrolled in genotype and phenotype registry, in general good health * participants who carry the genotype of interest, based on a buccal or blood derived dna sample exclusion criteria: * history of systemic lupus erythematosus, rheumatoid arthritis, or other autoimmune disease * history of cancer or lymphoma * current use of aspirin, prednisone, or nsaid or any immunosuppressant * self reported hiv
advanced mri in major depression

Conditions: Depressive Disorder, Major

Summary: depression is the most common psychiatric disorder. * 3-5% of a given population has major depression. * less than 50% of the depressed in denmark are diagnosed with major depression. * 25-50% of the depressed have a relative with major depression-underlying brain pathology? the purpose of this study is to use mri to evaluate cerebral morphology and function in ambulant patients with major depression

previous studies within major depression, have often included hospitalized patients with severe symptoms and imaging have been performed with pet and spect, which uses ionizing radiation. this study focus on ambulant patients(with or without medication/ect treatment), to find patients in an earlier stage. cerebral perfusion with the mr sequence arterial spin labelling, concentrations of different metabolites with mr spectroscopy and brain volumetry with bravo 3d t1 ax will be performed. mr protocol: t2 sag, t2 flair ax, asl ax, mrs and 3d t1 ax. scan time 45 min.

Eligibility criteria:
inclusion criteria: * patients who fulfil icd-10´s criteria for major depression, found within the ambulant psychiatric sector and who has a ham-d ≥ 18 exclusion criteria: * if the patient has pacemaker or other magnetic devices * pregnancy * has had an operation in the brain * bipolar disorder

Keywords: magnetic resonance imaging, magnetic resonance spectroscopy, perfusion, brain
allergy towards grass and bronchial inflammation - related to immunotherapy and exhaled nitrogen oxide

Conditions: Asthma, Bronchial; Allergic Rhinitis; Hypersensitivity, Immediate

Summary: the purpose of this study is to evaluate the immunomodulatory effect of treatment of allergic rhinitis symptoms with specific immunotherapy by measurement of pulmonary inflammatory markers, and among others, exhaled nitric oxide.


Eligibility criteria:
inclusion criteria: * age 18-45 years old * skin prick test or ras test and physical examination conclude that the patient will have a beneficial effect from specific immunotherapy exclusion criteria: * other diseases except atopic disease * pregnancy

Keywords: asthma allergic rhinitis atopy exhaled nitric oxide specific immunotherapy atopic diseases
can synbiotic use effect gut bacteria and the immune response in older people

Conditions: Aging

Summary: the objectives of this study are to use a nutritional change in the diet to improve gut health in older people. ageing can result in major changes in the composition and activities of the bacteria in your gut, leading to a higher incidence of gastrointestinal infections, decreased intestinal motility and impaired bowel function as people get older. this can result in constipation or diarrhoea, increased levels of inflammation and reduced immune response to infection. therefore, individuals aged 65 or over could benefit from safe and effective interventions that maintain a healthy balance of gut bacteria as well as restoring the immune response. bacteria in the gut are known to promote health. eating foods containing beneficial bacteria for example (probiotics) or food which contain substrates for the bacteria to grow on (prebiotics) can improve the balance of gut bacteria. the investigators will use a synbiotic with known anti-inflammatory properties, comprising a probiotic bifidobacterium longum strain and inulin (synergy 1), the synbiotic has been previously shown to be beneficial in reducing inflammation and to increase levels of beneficial bacteria in the gut in two studies in patients with inflammatory bowel disease. the investigators would now for these reasons, like to determine the effects of our synbiotic on the gut bacteria and immune function of older individuals in a double-blinded, crossover, placebo controlled, randomised investigation involving 40 volunteers for three months. the trial is designed so that participants will be assigned to receive the synbiotic preparation or the placebo for the first four weeks, this will be followed by four weeks without treatment, and then they will switch to the opposite preparation for another four weeks.


Eligibility criteria:
inclusion criteria: * 65-90 years * bmi 18.5-30.0 kg m2. exclusion criteria: * asplenia and other acquired or congenital immunodeficiencies * any autoimmune disease * connective tissue diseases * self-reported symptoms of acute or recent infection (including use of antibiotics within the previous 3 months) * taking probiotics or prebiotics, including lactulose for constipation * chronic gastrointestinal problems (e.g. inflammatory bowel disease, irritable bowel syndrome, cancer) * use of immunosuppressive or anti-inflammatory drugs.

Keywords: older people synbiotic prebiotic probiotic bacteria immune